Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.9052W HIGH $19.25
Volume
349.64 K
Value Traded
16.29 M
Short % Float
7.26%
+5.84%Week
+3.11%1 Month
+6.18%3 Month
+6.31%6 Month
+15.92%5 Year
+642.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.25 B
EPS (TTM)
2.36
P/E Ratio
7.10
Ent. Value
1.81 B
Total Shares
133.05 M
Float Shares
118.13 M
Insiders
11.21%
Institutions
58.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AUPH Catalyst Timeline
Dated clinical, regulatory and corporate events for Aurinia Pharmaceuticals Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aurinia Pharmaceuticals Inc
470Total events
2Upcoming
117Tier-1 (high impact)
2013 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationAritinerceptTrial
Clinical development initiated in four indications
autoimmune diseasessource ↗
▲Trial InitiationLUPKYNISApprovedTrial
Initiation of PRESERVE study investigating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab
lupus nephritissource ↗
▲Quarterly UpdateCorporate
Q1 2026 financial results: total revenue $77.7M, net product sales $73.6M, net income $34.4M
▲Type C MeetingzetomipzomibFDA Meeting
Positive FDA Type C meeting to accelerate zetomipzomib development in AIH
autoimmune hepatitissource ↗
▲Trial InitiationAritinerceptTrial
Initiated clinical study of aritinercept in one autoimmune disease
autoimmune diseasesource ↗
◆Trial InitiationAritinerceptTrial
Plan to initiate clinical study in an additional autoimmune disease in first half of 2026
autoimmune diseasesource ↗
●Trial InitiationAritinerceptTrial
Initiation of clinical studies for aritinercept in two autoimmune diseases
autoimmune diseasessource ↗
▲Full ResultsAritinerceptClinical Data
Positive Phase 1 study results for aritinercept
autoimmune diseasessource ↗
▲Quarterly UpdateLUPKYNISApprovedCorporate
LUPKYNIS Q3 2025 net product sales $70.6M, up 27% YoY
lupus nephritissource ↗
▲Quarterly UpdateLUPKYNISApprovedCorporate
LUPKYNIS net product sales $66.6M for Q2 2025
lupus nephritissource ↗
▲Full ResultsAritinerceptClinical Data
Positive Phase 1 results for aritinercept (AUR200) announced
autoimmune diseasessource ↗
◆Trial InitiationAritinerceptTrial
Plan to initiate clinical studies in at least two autoimmune diseases
autoimmune diseasessource ↗
▲Full ResultsAritinerceptClinical Data
Positive Phase 1 SAD results for aritinercept
autoimmune diseasessource ↗
◆Topline ReadoutAUR200Clinical Data
Initial results from Phase 1 study of AUR200 expected later this quarter
autoimmune diseasessource ↗
●Quarterly UpdateCorporate
Full year 2025 total revenue and net product sales guidance provided
▲Quarterly UpdateLUPKYNISApprovedCorporate
2025 LUPKYNIS net product sales guidance raised to $265M-$270M
lupus nephritissource ↗
▼Restructuring LayoffsCorporate
Strategic restructuring with ~45% workforce reduction announced
▲First Patient DosedAUR200Trial
First participant dosed in Phase 1 study of AUR200
autoimmune diseasessource ↗
▲Milestone PaymentLUPKYNISApprovedCorporate
$10 million milestone payment recognized from Otsuka for Japanese approval
lupus nephritissource ↗
▲First Patient DosedAUR200Trial
First patients expected to enter Phase 1 SAD study of AUR200
autoimmune diseasessource ↗
▼Restructuring LayoffsCorporate
Employee headcount reduction of at least 25% by end of Q1 2024
▼Program DiscontinuationAUR300DiscontinuedCorporate
Discontinuation of AUR300 pre-clinical development program
▲Milestone PaymentLUPKYNISApprovedCorporate
European pricing and reimbursement milestone achieved triggering $10M payment from Otsuka
lupus nephritissource ↗
▲Full ResultsLUPKYNISApprovedClinical Data
Full results from AURORA 2 published in Arthritis Rheumatology
lupus nephritissource ↗
▲Other Regulator MilestoneLUPKYNISApprovedEx-US Regulatory
LUPKYNIS received marketing acceptance in Scotland by Scottish Medicines Consortium
lupus nephritissource ↗
●Runway Guidance UpdateCorporate
Narrowing 2023 net product revenue guidance to $155-$160 million
◆Oral PresentationLUPKYNISApprovedPresentation
14 LUPKYNIS clinical abstracts accepted for presentation at ASN and ACR November 2023
lupus nephritissource ↗
▲Milestone PaymentLUPKYNISApprovedCorporate
$10.0 million pricing and reimbursement milestone from Otsuka in September 2023
lupus nephritissource ↗
▲Quarterly UpdateLUPKYNISApprovedCorporate
2023 revenue guidance raised to $150-$160M
lupus nephritissource ↗
▲Full ResultsLUPKYNISApprovedClinical Data
Full results of AURORA 2 extension study published in Arthritis Rheumatology
lupus nephritissource ↗
Past FDA Catalysts and PDUFA Decisions
How AUPH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | AUR200 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$96M
Pipeline Value
$1.3B
Commercial Value
Overvalued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 53%
Small Cap(rank 349 of 658)
Percentile Rank
Aurinia Pharmaceuticals Inc faces pipeline headwinds (35/100), with $147M risk-adjusted pipeline value, led by 0.05% Voclosporin in Dry Eye Syndrome (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $311.5M x 4.3 = $1.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| LUPKYNIS | $298M | $240M | +24.3% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.05% Voclosporin Small moleculeCompletedNCT04147650 | Dry Eye Syndrome | Phase 2 | COMPLETED | 508 | Oct 8, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every AUPH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| aritinercept | autoimmune diseases | Phase 1 | 2025-06-30 | immunoglobulin A reduction: up to 48%; immunoglobulin M reduction: 55%; immunoglobulin G reduction: 20%Read More | Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Robertson Stephen P.Officer (Chief Legal Officer) | Sell | -11,939 588,848 held | $15.95 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AUPH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 10.1 % (9.8 %) | 221.36 M | 13.04 M | 6.66% ( 814.61 K) |
AUPH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AUPH ranks across every disease it competes in
Competitive Position is a premium feature
See how AUPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAUPH News
AUPH▲ +6.2%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals has released its financial results for the three and six months ended June 30, 2026. The report includes an update on the company's recent business progress, indicating a positive trajectory. Further details on financial performance and strategic initiatives were also highlighted.
Read more →AUPHAurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals has announced the initiation of the PRESERVE study. This clinical trial will investigate the combination of LUPKYNIS with Belimumab, Obinutuzumab, or Anifrolumab in patients suffering from lupus nephritis. The study aims to assess the efficacy of these combinations in treating this condition.
Read more →AUPH▼ -6.8%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported a total revenue of $77.7 million for the three months ended March 31, 2026, a 24% increase from the same period in 2025. The net product sales for LUPKYNIS were $73.6 million, representing a 23% growth. The company also reported a net income of $34.4 million, a 48% increase year-over-year. Additionally, Aurinia reiterated its 2026 guidance, projecting total revenue between $315 million and $325 million.
Read more →AUPHAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Aurinia Pharmaceuticals has entered into a definitive agreement to acquire Kezar Life Sciences for $6.955 per share, alongside contingencies related to ongoing development projects. This merger, beneficial for both companies, aims to leverage Aurinia's expertise in autoimmune therapies and Kezar's promising drug, zetomipzomib. The transaction is expected to close in the second quarter of 2026, subject to various conditions. Notably, the deal includes a contingent value right for shareholders of Kezar, enhancing potential financial benefits.
Read more →AUPHAurinia Announces Management Transition
Aurinia Pharmaceuticals has announced a management transition where Kevin Tang will take over as CEO from Peter Greenleaf, who will remain as a consultant. The company expresses gratitude for Greenleaf's contributions during his seven-year tenure. Aurinia maintains a strong position in the biopharmaceutical market, highlighted by the success of its drug LUPKYNIS for lupus nephritis and the ongoing development of aritinercept. A new management team has been appointed to support the company's future direction in delivering treatments for autoimmune diseases.
Read more →AUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported financial results for the year ending December 31, 2025, highlighting a cash position of $398 million and a significant increase in LUPKYNIS sales. The company anticipates total revenue between $315 million and $325 million for 2026, reflecting an 11% to 15% increase. Aurinia is also advancing its dual inhibitor, aritinercept, with plans for clinical studies in autoimmune diseases.
Read more →AUPH▲ +8.4%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Inc. has reported robust financial results for Q3 and the first nine months of 2025, showcasing a marked growth in LUPKYNIS sales by 27%. The company raised its revenue guidance to between $275 million to $280 million for the full year. Notably, net income saw a staggering increase, with a net profit margin improvement across both reporting periods. Additionally, positive progress was noted in clinical trials for their new drug aritinercept aimed at treating autoimmune diseases.
Read more →AUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Aurinia Pharmaceuticals Inc. reported strong financial results for the second quarter and first half of 2025, with total revenues of $70 million and $132.5 million, representing significant year-over-year growth. Net product sales for its drug LUPKYNIS also increased, reaching $66.6 million and $126.5 million. The company announced an increase in its revenue guidance for the full year 2025, reflecting optimism about future sales. In addition, positive results from a Phase 1 trial of aritinercept were highlighted, suggesting potential advancements in their product pipeline.
Read more →AUPHAurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins
Aurinia Pharmaceuticals announced positive results from a Phase 1 study of aritinercept (AUR200), a dual inhibitor targeting B cell-activating factor and a proliferation-inducing ligand. The drug demonstrated robust and sustainable reductions in immunoglobulins, indicating potential efficacy. Aritinercept was well tolerated at all tested dose levels, with minimal adverse events reported. The company plans to initiate further clinical studies for autoimmune diseases in the latter half of the year.
Read more →AUPHAurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 ROCKVILLE, Maryland and EDMONTON, Alberta - May 12, 2025 - Aurinia Pharmaceuticals Inc. (NASDAQ AUPH) today announced financial results for the three months ended March 31, 2025.
Aurinia Pharmaceuticals has announced its financial results for the first quarter of 2025, reporting a total revenue of $62.5 million, a significant increase from $50.3 million in the same period last year. Net product sales of LUPKYNIS reached $60.0 million, marking a 25% rise, reflecting strong adoption in the market. The company also achieved a net income of $23.3 million, a turnaround from a loss in the previous year. Aurinia expects total revenue for 2025 to remain in the range of $250 million to $260 million. Additionally, the company plans to report initial results from its Phase 1 study of AUR200 later this quarter.
Read more →AUPH▼ -5%on this news
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended
Aurinia Pharmaceuticals reported a strong financial performance for both the fourth quarter and full year ending December 31, 2024. Revenue for Q4 rose 33% to $59.9 million, driven largely by a 36% increase in net product sales of LUPKYNIS, which reached $57.6 million. The company also reported a net income of $1.4 million for Q4, a remarkable recovery from a loss of $(26.9) million in the prior year. Looking ahead, Aurinia expects 2025 total revenue to range between $250 million and $260 million, reflecting optimistic growth prospects.
Read more →AUPH▲ +10.9%on this news
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development Achieved $67.8
Aurinia Pharmaceuticals has reported strong financial results for the third quarter of 2024, achieving $67.8 million in total net revenue, reflecting a 24% year-over-year growth. The company announced a strategic restructuring plan aimed at streamlining operations, focusing on enhancing the LUPKYNIS franchise, and accelerating the development of AUR200. While the restructuring is expected to result in significant operational cost savings, it will also involve a substantial workforce reduction. Overall, Aurinia maintains a positive outlook, reiterating its revenue guidance for the year.
Read more →AUPHAurinia Announces Board Restructuring Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director The Board has acc
Aurinia Pharmaceuticals Inc. has announced a restructuring of its Board of Directors to better align with shareholder interests. Peter Greenleaf continues as a director, despite a conditional resignation, due to the board's determination of exceptional circumstances. Kevin Tang has been appointed to the board, bringing over 20 years of experience in the biopharmaceutical industry. Additionally, three directors have submitted their conditional resignations following a lack of majority support at the recent Annual General Meeting.
Read more →AUPHAURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of
Aurinia Pharmaceuticals reported its financial results for the second quarter of 2024, showcasing a total net revenue of $57.2 million, a 38% increase from the previous year. The company also generated $15.8 million in free cash flow, enhancing its financial stability. Aurinia is moving forward with its development of AUR200, a new treatment targeting autoimmune diseases, and is anticipating approval for LUPKYNIS in Japan later this year. The company has adjusted its net product revenue guidance to between $210 and $220 million for 2024.
Read more →AUPH▼ -24.5%on this news
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value Total net revenue was $45.1 million and $175.5 million, and net product revenue was $4
Aurinia Pharmaceuticals reported significant financial results for 2023, with total net revenue of $175.5 million, reflecting a 31% year-over-year increase. The company confirmed a net product revenue guidance of $200 - $220 million for 2024. As part of their updated strategy, Aurinia will discontinue its AUR200 and AUR300 programs, leading to a one-time charge of $11 - $15 million but anticipates annual operational cost savings of $50 - $55 million. Additionally, the company announced a share repurchase program of up to $150 million, signaling confidence in its growth prospects.
Read more →AUPH▲ +10.5%on this news
AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS Net product revenue of $40.8 million for the third quarter of 2023 an increase of 60% over the prior year third quarter
Aurinia Pharmaceuticals reported robust financial results for Q3 2023, with net product revenue reaching $40.8 million, marking a 60% increase compared to Q3 2022. The total net revenue for the nine months ended September 30, 2023, also increased by 24% year-over-year. The company secured a $10 million milestone from Otsuka Pharmaceutical due to pricing approvals in major European markets and has narrowed its revenue guidance for 2023. Despite some decreases in total net revenue and collaboration revenues, Aurinia continues to show growth in the market for its lupus nephritis treatment, LUPKYNIS.
Read more →AUPHAURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS Net revenue increased to $41.5 million for second quarter of 2023 47% over the prior year second quarter Increases 2023
Aurinia Pharmaceuticals reported strong financial results for the second quarter of 2023, with a net revenue of $41.5 million, marking a 47% increase compared to the previous year. The company raised its revenue guidance for the year to a range of $150 to $160 million, reflecting positive commercial performance of its product LUPKYNIS. Additionally, clinical studies have affirmed the drug's efficacy in treating lupus nephritis. However, the company continues to face high operational costs.
Read more →AUPHAURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023 an increase of 59% over the first quarter of the prior year Increases 2023 r
Aurinia Pharmaceuticals reported a significant increase in net revenue for Q1 2023, reaching $34.4 million, a 59% rise compared to the same period last year. The company has boosted its revenue guidance for 2023, anticipating sales of $135 to $155 million, driven by the performance of its drug LUPKYNIS. Additionally, strong patient metrics show consistent conversion rates and improved patient persistency on therapy. However, the company reported a net loss of $26.2 million for the quarter, though this represents an improvement from the previous year’s losses.
Read more →AUPHAurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial LUPKYNIS treated patients showed histologic activity improvement with stable chronicity scores similar to active co
Aurinia Pharmaceuticals announced promising results from the AURORA Trial's Renal Biopsy Sub-Study, indicating that LUPKYNIS-treated patients showed significant histologic activity improvement while maintaining stable chronicity scores. The findings suggest LUPKYNIS's effectiveness is on par with the current standard of care, while highlighting its differentiation from first-generation calcineurin inhibitors. The company aims to share further details at the upcoming Congress of Clinical Rheumatology meeting. The results underscore the potential long-term efficacy and safety of LUPKYNIS in treating lupus nephritis.
Read more →AUPH▲ +9.1%on this news
AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full
Aurinia Pharmaceuticals reported strong financial results for Q4 and full year 2022, with total net revenue reaching $28.4 million in the quarter and $134.0 million for the year, marking a significant year-over-year increase of 194%. The company continues to improve patient outreach for its product LUPKYNIS, evidenced by a rising number of patients on therapy and improved conversion rates. However, Aurinia still faces challenges with net losses and a decrease in newly added PSFs in the recent quarter. The company reaffirms its revenue guidance for the fiscal year 2023, signaling confidence in ongoing sales growth.
Read more →About Aurinia Pharmaceuticals Inc
Headquarters#140, 14315 - 118 AVENUE, EDMONTON, A0, T5L 4S6
Founded1993
BIOPHARMAWATCH ELITE PLUS
Trade the next AUPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime